INCYTE CORPORATION (INCY): what the price requires
At today's price, INCYTE CORPORATION (INCY) is priced for +3.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/INCY
Headline
| Field | Value |
|---|---|
| Ticker | INCY |
| Company | INCYTE CORPORATION |
| Current price | $114.70/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 3.7% |
| Operating margin today | 30.2% |
| Margin compression implied | -26.5pp |
| Implied growth | 3.2% |
| Multiple paid | 16x operating income |
The operating-margin requirement is derived from the framework's value band at year 8, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~5.5pp.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | +0.39σ |
| cohort percentile (of 112 peers) | 29 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.53x | 5 | expensive |
| Earnings | 1.40x | 5 | expensive |
| Relative | 0.66x | 5 | justifies |
| Growth | 0.72x | 3 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $260.55 | 0.44x | yes | FCF base $1.7B, growth 21% (input: historical growth), terminal g 4.0%, WACC 9.2%, 6yr projection |
| DCF Exit Multiple | Growth | $158.45 | 0.72x | yes | Exit EV/EBITDA: 10.5x / 12.5x / 14.5x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $203.18 | 0.56x | yes | P/E 28x (static sector reference · 2026-04), scenarios: 22.8x / 28.0x / 33.2x (bear / base = reference held flat / bull), EV/EBITDA 20x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $74.84 | 1.53x | yes | BV/sh $27.19, ROE (TTM) 25.5%, ke 9.3% |
| Two-Stage Excess Return | Asset | $125.08 | 0.92x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $128.49 | 0.89x | yes | Rev $5.4B, growth 21% (input: historical growth; tapered), Terminal P/S: 3.6x / 4.4x / 5.2x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $84.96 | 1.35x | yes | EPS $7.08, growth 2% (input: historical EPS growth), PEG=10.41 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $47.19 | 2.43x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.72B × (1−12%) / WACC 9.2% → EPV (no growth) |
| Residual Income | Asset | $110.99 | 1.03x | yes | BV $27.19 + 5yr PV of (ROE (TTM) 25.5% − Kₑ 9.3%) × BV; BV grows 8.8%/yr |
| Graham Number | Asset | $65.81 | 1.74x | yes | √(22.5 × EPS $7.08 × BVPS $27.19) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $173.67 | 0.66x | yes | EBITDA $1.63B × sector EV/EBITDA 20.0x |
| FCF Yield | Earnings | $94.89 | 1.21x | yes | FCF $1516.8M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $81.70 | 1.40x | yes | SBC-adj FCF $1.26B (FCF $1.52B − SBC $0.25B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $228.45 | 0.50x | yes | EPS $7.08 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $32.95 | 3.48x | yes | BV $27.19 × (ROIC 11.1% / WACC 9.2%) |
| P/Sales Sector | Relative | $155.52 | 0.74x | yes | Revenue $5.36B × sector P/S 6.0x |
| PEG Fair Value | Relative | $265.50 | 0.43x | yes | EPS $7.08 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $76.54 | 1.50x | yes | EPS $7.08 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $4.0b |
| Net debt / NOPAT (after-tax) | -3.05x (net cash) |
| Net debt / operating income (pre-tax) | -2.69x (net cash) |
| Interest coverage | 612.9x |
| Share count CAGR (buyback) | -1.9% |
| Burning cash | no |
Bullet Takeaways
- Incyte is a profitable biopharma built on Jakafi, its blood-cancer drug, which alone generated about $3.09 billion in 2025, with a second franchise in the skin cream Opzelura and a growing hematology-oncology portfolio behind it.
- The defining risk is concentration meeting a clock: Jakafi loses patent protection in 2028, and the entire investment case turns on whether new products replace that revenue before generics arrive.
- Watch the launch cadence; management guides 2026 total product revenue to $4.77 to $4.94 billion and targets $3 to $4 billion of non-Jakafi revenue by 2030, the bridge across the patent cliff.
Bull Case
Valuing a profitable biopharma is its own discipline, because the standard cash-flow methods systematically misjudge it. They capitalize today's earnings, but a drug company is really a portfolio of patent-protected cash streams with known expiration dates and a pipeline of binary outcomes that the methods cannot price. Incyte is the clearest version of this puzzle: it earns a 30% operating margin and sits on about $4 billion of net cash, with essentially no debt and interest covered hundreds of times over. On the surface that is a fortress, and the relative and growth-based methods actually read the price as cheap, below where they land. The catch is that the cash flow is concentrated in one drug, and the market is pricing the question every biopharma faces, which is what happens when the patent runs out.
The bull answer is that Incyte is well underway building the replacement. The current franchises are still growing: Jakafi rose 11% in 2025 to $3.09 billion, Opzelura rose 20% in Q1 2026 to $143 million, and the hematology and oncology products jumped 116% in the quarter to $204 million on Niktimvo, Monjuvi, and Zynyz. That last number is the tell: a new portfolio is scaling fast off a small base. Management has laid out a concrete bridge, targeting four major product launches across 2026 and 2027, including an extended-release Jakafi formulation, Opzelura's European expansion, Monjuvi in first-line large B-cell lymphoma, and povorcitinib, with each franchise aimed at $1 billion-plus potential.
The balance sheet is what funds the bridge without dilution. Four billion dollars of net cash lets Incyte reinvest aggressively into launches and trials while still buying back stock, with the share count edging lower rather than higher. A biotech approaching a patent cliff with a net-cash hoard, a growing second and third franchise, and a 30% operating margin to fund the transition is in a far stronger position than the typical one-drug company staring down generics with an empty pipeline and a thin balance sheet. The bull case is that the market is anchoring on the 2028 cliff while underweighting the pipeline that management is targeting to grow non-Jakafi revenue to $3 to $4 billion by 2030.
Bear Case
The advantage being chipped away is the patent wall around Jakafi, and the calendar is fixed. Incyte's own filing describes the threat directly: a generic manufacturer has sought approval with "a paragraph IV certification purporting to challenge one or more patents covering ruxolitinib composition of matter and its use", the legal mechanism by which generics enter once exclusivity lapses in 2028. Jakafi is not one product among many; at roughly $3.09 billion it is the majority of Incyte's revenue. When a single drug that large goes generic, the revenue does not erode gently, it falls off a cliff, often losing the bulk of sales within a couple of years. The 30% operating margin and the net-cash fortress both rest on a franchise with a known expiration date, and the market knows it, which is why the multiple sits at the very top of the peer distribution while the methods say the price is supported only if the replacement revenue actually shows up.
The replacement is the bear's real doubt, because pipeline math rarely lands on schedule. Management's plan depends on four launches across 2026 and 2027 all succeeding and scaling, and the early evidence is mixed: the weaker Opzelura revenue forecast for 2026 has already raised concern about whether the second franchise grows fast enough to matter against the Jakafi hole. Each new product carries its own risks, clinical, regulatory, competitive, and commercial, and the bear case is not that any one fails but that the portfolio as a whole arrives smaller or later than the bridge requires. A company that needs $3 to $4 billion of new revenue by 2030 to offset a 2028 cliff is running a tight timeline with little room for a single launch to disappoint.
The competitive dynamic compounds it. The filing notes that demand for Incyte's products "may be reduced or eliminated if our competitors develop or acquire and commercialize generic or branded products that are safer or more effective". The new franchises Incyte is counting on do not enter empty markets; they compete against entrenched therapies and other companies' pipelines. The balance sheet means this is not a solvency bear; Incyte will not run out of money. The bear case is about the gap between a fixed loss and an uncertain replacement: the price assumes the transition succeeds, and if the pipeline underdelivers, the premium multiple compresses toward where the cliff-aware methods sit, and the net cash cushions the fall without preventing it.
Valuation
The price embeds a modest-sounding assumption that hides a sharp question. At about $98 (June 27, 2026) Incyte trades near 28 times operating income, and inverting that says the market is paying for company-wide operating growth around 9% a year for five years, a pace within what Incyte has recently delivered and one most comparable companies have sustained. For most businesses that would be unremarkable. For Incyte it is not, because the five years in question straddle the 2028 Jakafi patent cliff, so steady 9% growth implicitly assumes the new portfolio more than fills the hole the largest product leaves.
The methods we use to triangulate split in a way that captures the bet precisely. The relative peer-multiple and the growth-based methods read the price as supported, landing at or below the current level, because they credit the cash flow and the forward pipeline. The asset-based lens reads slightly rich. The signal here is not that the price is broadly above every method, as it is for many premium names, but that the price is value-supported on the methods that look forward and only mildly stretched on the backward-looking ones. The tension to reconcile is that the multiple sits at the very top of the biopharma peer distribution even as the forward methods call it cheap: the market is paying a high headline multiple on current earnings precisely because it expects the pipeline to convert today's concentrated franchise into a diversified one, so the peer comparison and the forward read are answering different questions on different bases.
Solvency is the strongest single fact and bounds the downside firmly. Incyte holds about $4 billion of net cash against almost no debt, with interest coverage in the hundreds and a share count that has edged lower. That cash is not just a safety net; it is the funding for the launches that have to work, which means the company controls its own bridge rather than depending on markets to finance it. What bounds the downside is therefore the net cash plus the value of the existing franchises even in a pessimistic pipeline scenario, not a leverage risk. The buyer at this price is underwriting a successful transition across the 2028 cliff, paid for out of a fortress balance sheet, with the existing drugs and the cash as the floor if the pipeline arrives smaller than planned.
Catalysts
The recent results show the portfolio rotating in real time. For full-year 2025, Jakafi net product revenue rose 11% to $3.09 billion on a 9% increase in paid demand. In Q1 2026, Jakafi grew 7% to $758 million, Opzelura grew 20% to $143 million on demand in both atopic dermatitis and vitiligo, and the hematology and oncology products surged 116% to $204 million driven by Niktimvo, Monjuvi/Minjuvi, and Zynyz. The newer franchises are scaling fast off a small base, which is exactly the pattern the bridge across the patent cliff needs.
The forward catalysts are dense and dated. Management guides 2026 total net product revenue to $4.77 to $4.94 billion, with Jakafi at $3.22 to $3.27 billion including the initial launch of an extended-release Jakafi formulation if approved, Opzelura at $750 to $790 million including an ex-U.S. moderate-atopic-dermatitis launch in late 2026, and hematology and oncology at $800 to $880 million. Beyond the year, management targets four major launches across 2026 and 2027, including Monjuvi in first-line large B-cell lymphoma and povorcitinib, and a goal of $3 to $4 billion in non-Jakafi revenue by 2030. Each launch milestone and each regulatory decision is a catalyst, because together they determine whether the replacement revenue arrives in time for the 2028 cliff.
Peer Cohorts (Per Segment, With Filing Citations)
Oncology and dermatology pharmaceuticals (single segment) (reported)
- EXEL (EXELIXIS, INC.)
- (no filing in the citation store)
- JAZZ (Jazz Pharmaceuticals plc)
- (no filing in the citation store)
- NBIX (NEUROCRINE BIOSCIENCES, INC.)
- (no filing in the citation store)
- HALO (HALOZYME THERAPEUTICS, INC.)
- (no filing in the citation store)
- SUPN (SUPERNUS PHARMACEUTICALS, INC.)
- (no filing in the citation store)
- ALKS (Alkermes plc.)
- (no filing in the citation store)
- CORT (CORCEPT THERAPEUTICS INC)
- (no filing in the citation store)
- AXSM (AXSOME THERAPEUTICS, INC.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Incyte FY2025 results, 8-K · Incyte 2026 guidance · Incyte Q1 2026 results, 8-K · Incyte 2026 guidance commentary